摘要
目的:探讨国家药品集中带量采购(以下简称集采)对医药企业创新投入的影响及作用机制。方法:基于2015—2023年上市公司数据,采用交错双重差分模型,以前8轮国家药品集采为准自然实验,控制行业和年份固定效应,检验集采对医药企业创新投入的影响,进行平行趋势和安慰剂检验,验证结果的稳健性。结果:集采显著增加中标企业的创新投入,中标企业下一季度的研发费用较营业收入的比值增加1.40%。集采通过提升企业成本效率和强化行业市场竞争,促进创新投入。结论:集采显著增加中标企业的创新投入,提升成本效率是提高企业创新投入的重要影响路径,行业市场竞争对集采与企业创新投入存在显著调节效应,可从创新激励、沟通体系、市场竞争等方面完善国家药品集采制度。于:(1)引入动态双重差分模型,验证了集采对中标企业创新投入的促进作用。(2)从企业成本效率和行业市场竞争2个维度,深入探究集采对中标企业创新投入的影响路径,有助于全面理解集采政策的作用机制。(3)基于对影响路径的分析,为集采提供更具针对性的决策参考,也有益于促进医药行业实现创新驱动的高质量发展。
Objective:The impact and mechanism system of the National Centralized Volume-Based Procurement(NCVBP)on innovation investment in pharmaceutical companies.Methods:Based on listed company data from 2015 to 2023,it uses the first eight rounds of NCVBP as a quasi-natural experiment and applies a staggered difference-in-differences model to control the industries and year fixed effects,test the impact of NCVBP on innovation investment in pharmaceutical companies,conduct the parallel trend and placebo test,and verify the robustness of the results.Results:The innovation investment of the winning enterprises was significantly increased by NCVBP.The ratio of Research&Development expenses to operating revenues of winning firms in the next quarter increases by 1.4%.The centralized procurement promotes innovation investment by enhancing the cost efficiency of enterprises and strengthening market competition in the industry.Conclusion:Collective purchasing significantly increases the innovation investment of winning enterprises,the improvement of cost efficiency is an important influence path to improve the innovation investment of enterprises.The industry market competition has a significant moderating effect on the collective purchasing and the innovation investment of enterprises;the national drug collective purchasing system can be improved from the aspects of innovation incentives,communication system,market competition,and so on.
作者
许智凯
孟光兴
Xu Zhikai;Meng Guangxing(School of Medical Business,Guangdong Pharmaceutical University,Zhongshan,Guangdong,528400,China;不详)
出处
《中国卫生经济》
北大核心
2025年第5期80-85,共6页
Chinese Health Economics
基金
广东省科学技术厅2020年软科学项目(2020A1010020050)
广东省药品监督管理局2024年科技创新项目(2024ZDZ10)
广东省科学技术厅2022年海外名师项目(粤财科教[2022]184号)。
关键词
药品集中带量采购
交错双重差分模型
医药企业
创新投入
作用机制
National Centralized Volume-Based Procurement
staggered difference-in-differences model
pharmaceutical enterprise
Research&Development investment
effect mechanism
